|
|
|||
|
||||
OverviewFrom humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here Full Product DetailsAuthor: Christian Rommel , Bart Vanhaesebroeck , Peter K. Vogt , Peter K VogtPublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: 2011 ed. Volume: 346 Dimensions: Width: 15.50cm , Height: 2.80cm , Length: 23.50cm Weight: 0.705kg ISBN: 9783642136627ISBN 10: 3642136621 Pages: 310 Publication Date: 01 October 2010 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: In Print This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||